Cover Image
市場調查報告書

細胞凋亡蛋白質1 (CD279,全身性紅斑性狼瘡致病性2,PD1) - 開發中產品分析

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358697
出版日期 內容資訊 英文 221 Pages
訂單完成後即時交付
價格
Back to Top
細胞凋亡蛋白質1 (CD279,全身性紅斑性狼瘡致病性2,PD1) - 開發中產品分析 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 221 Pages
簡介

細胞凋亡蛋白質1,又稱作PD-1和CD279,是藉由PDCD1遺傳基因編碼的蛋白質。PD-1是屬於免疫球蛋白超分子群之細胞表面受體,可於T細胞和專業B細胞上發現。

本報告提供細胞凋亡蛋白質1 (CD279,全身性紅斑性狼瘡致病性2,PD1)的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品
  • 階段不明的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Agenus, Inc.
  • Aurigene Discovery Technologies Limited
  • BeiGene, Ltd.
  • Cellular Biomedicine Group, Inc.
  • CytomX Therapeutics, Inc.
  • Enumeral Biomedical Holdings, Inc.
  • GlaxoSmithKline Plc
  • Globavir Biosciences, Inc.
  • Immunovo BV
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Jounce Therapeutics, Inc.
  • MacroGenics, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merus B.V.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Regeneron Pharmaceuticals, Inc.
  • Sorrento Therapeutics, Inc.
  • Sutro Biopharma, Inc.
  • Symphogen A/S
  • Tasly Pharmaceutical Group Co., Ltd.
  • Tesaro, Inc.
  • Theravectys SA
  • Tikcro Technologies, Ltd.
  • Vyriad

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0520TDB

Summary

Global Markets Direct's, 'Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016', provides in depth analysis on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)
  • The report reviews Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Overview
  • Therapeutics Development
    • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Stage of Development
    • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Therapy Area
    • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Indication
  • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Companies
  • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Universities/Institutes
  • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Companies Involved in Therapeutics Development
    • Aduro BioTech, Inc.
    • Agenus, Inc.
    • Aurigene Discovery Technologies Limited
    • BeiGene, Ltd.
    • Beijing Hanmi Pharmaceutical Co., Ltd.
    • BIOCAD
    • Cellular Biomedicine Group, Inc.
    • CytomX Therapeutics, Inc.
    • Eli Lilly and Company
    • Enumeral Biomedical Holdings, Inc.
    • Immunovo BV
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Jounce Therapeutics, Inc.
    • Les Laboratoires Servier SAS
    • MacroGenics, Inc.
    • MD Biosciences GmbH
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Molecular Partners AG
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • PharmaEssentia Corporation
    • Pieris Pharmaceuticals Inc
    • Regeneron Pharmaceuticals Inc
    • Sutro Biopharma, Inc.
    • Symphogen A/S
    • Tasly Pharmaceutical Group Co., Ltd.
    • Tesaro, Inc.
    • Theravectys SA
    • Tikcro Technologies, Ltd.
    • Vyriad
    • Xencor, Inc.
  • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drug Profiles
    • AM-0001 - Drug Profile
    • AMP-224 - Drug Profile
    • Anti-PD1 Monoclonal Antibody + Cellular Immunotherapy for Glioblastoma - Drug Profile
    • AUR-012 - Drug Profile
    • BGB-108 - Drug Profile
    • BGBA-317 - Drug Profile
    • Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile
    • Drug to Inhibit PD-1, Gal-9 and TIM-3 for Solid Tumor - Drug Profile
    • durvalumab + MEDI-0680 - Drug Profile
    • ENUM-003 - Drug Profile
    • ENUM-388D4 - Drug Profile
    • GXP-2 - Drug Profile
    • IBI-308 - Drug Profile
    • JS-001 - Drug Profile
    • MD-402 - Drug Profile
    • mDX-400 - Drug Profile
    • MEDI-0680 - Drug Profile
    • MGD-013 - Drug Profile
    • Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile
    • Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile
    • Monoclonal Antibodies to Antagonize PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile
    • Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile
    • Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile
    • Monoclonal Antibody to Antagonize PD-1 for Autoimmune Disorders and Oncology - Drug Profile
    • Monoclonal Antibody to Antagonize PD-1 for Non-Small Cell Lung Cancer - Drug Profile
    • Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile
    • Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile
    • Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile
    • Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile
    • Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile
    • Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile
    • Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology - Drug Profile
    • Monoclonal Antibody to Inhibit PD-1 for Cancer - Drug Profile
    • Monoclonal Antibody to Inhibit PD-1 for HIV - Drug Profile
    • Monoclonal Antibody to Inhibit PD-1 for Oncology - Drug Profile
    • Monocloncal Antibody to Inhibit PD-1 for Oncology - Drug Profile
    • nivolumab - Drug Profile
    • Oncolytic Virus to Activate IFNb for Head and Neck Cancer and Lewis Lung Cancer - Drug Profile
    • pazopanib hydrochloride + pembrolizumab - Drug Profile
    • PD-1 Antagonist + ropeginterferon alfa-2b - Drug Profile
    • PDR-001 - Drug Profile
    • PEGMP-7 - Drug Profile
    • pembrolizumab - Drug Profile
    • PF-06801591 - Drug Profile
    • PRS-332 - Drug Profile
    • Recombinant Protein to Inhibit VEGF-A and PD1 for Solid Tumor and Hematological Malignancies - Drug Profile
    • REGN-2810 - Drug Profile
    • SHR-1210 - Drug Profile
    • SNPD-07 - Drug Profile
    • STIA-1110 - Drug Profile
    • TSR-042 - Drug Profile
    • Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile
    • Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile
    • Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile
    • XmAb-20717 - Drug Profile
  • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Dormant Projects
  • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Discontinued Products
  • Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Aduro BioTech, Inc., H2 2016
  • Pipeline by Agenus, Inc., H2 2016
  • Pipeline by Aurigene Discovery Technologies Limited, H2 2016
  • Pipeline by BeiGene, Ltd., H2 2016
  • Pipeline by Beijing Hanmi Pharmaceutical Co., Ltd., H2 2016
  • Pipeline by BIOCAD, H2 2016
  • Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • Pipeline by CytomX Therapeutics, Inc., H2 2016
  • Pipeline by Eli Lilly and Company, H2 2016
  • Pipeline by Enumeral Biomedical Holdings, Inc., H2 2016
  • Pipeline by Immunovo BV, H2 2016
  • Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Pipeline by Jounce Therapeutics, Inc., H2 2016
  • Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Pipeline by MacroGenics, Inc., H2 2016
  • Pipeline by MD Biosciences GmbH, H2 2016
  • Pipeline by MedImmune, LLC, H2 2016
  • Pipeline by Merck & Co., Inc., H2 2016
  • Pipeline by Molecular Partners AG, H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Pipeline by PharmaEssentia Corporation, H2 2016
  • Pipeline by Pieris Pharmaceuticals Inc, H2 2016
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Pipeline by Sutro Biopharma, Inc., H2 2016
  • Pipeline by Symphogen A/S, H2 2016
  • Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016
  • Pipeline by Tesaro, Inc., H2 2016
  • Pipeline by Theravectys SA, H2 2016
  • Pipeline by Tikcro Technologies, Ltd., H2 2016
  • Pipeline by Vyriad, H2 2016
  • Pipeline by Xencor, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top